



Research | Awareness | Support

A taste of
**The Brain
Tumour
Charity**

thebraintumourcharity.org

Our Annual Report 2016/17

Annual Report and Accounts

2016 - 2017

Contents

	Page
1. Report of the trustees	2
2. Statement of the trustees' responsibilities	19
3. Independent auditor's report	20
4. Statement of financial activities	22
5. Balance sheet	23
6. Cash flow statement	24
7. Notes to the financial statements	25

Report of the trustees for the year ended 31 March 2017

The trustees, who are also directors of The Charity for the purpose of the Companies Act, present their annual report together with the consolidated financial statements for The Charity and its subsidiary (together, 'the Group') for the year ended 31 March 2017, which are prepared to meet the requirements for a directors' report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice ('SORP') applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP)."

Please note that coffee is referenced throughout this report as a chosen theme. All stakeholders who received the physical format of the annual review also received a bag of *The Brain Tumour Charity Blend* coffee, generously donated by 200 Degrees Coffee.

Chair and CEO's report



It is a privilege to chair The Brain Tumour Charity and, in particular, to work alongside so many staff and fellow trustees who have been affected by this terrible disease – either personally or, most tragically, through the death of a child – and whose response has been to ensure that the devastating impact of brain tumours is reduced.

In 2016/2017, The Charity invested in several landmark initiatives to speed up the search for new treatments. These included The Everest Centre, to improve life for children living with low grade tumours, and the Brain Tumour Impact Fund, a first-of-its-kind, brain-tumour-focused Venture

Philanthropy Fund, for the development of new therapies. We committed £6.8 million towards research and formed two Scientific Advisory Boards to ensure that all projects funded were the best available globally. An exceptional achievement for The Charity during the year included our role in further reducing the average childhood brain tumour diagnosis time to 6.5 weeks.

The challenges facing us remain immense. The astonishing and most welcome improvements in the recovery rates for almost all cancers have not been seen with brain cancer, and the nature of living with a brain tumour is frequently exceptionally challenging. We will continue to seek a cure and to support those affected by the disease.

Sir Martin Narey

Chair of Trustees, The Brain Tumour Charity



At The Brain Tumour Charity, we know there's no time to waste in our search for a cure. To get results we need to act and we need to act quickly. However, we also know that in order to achieve our vision – a world where brain tumours are defeated – we must put solid foundations in place.

That's why, like coffee farmers who handpick and plant the best seeds to produce the highest quality coffee, we've spent the year carefully selecting the research, projects and initiatives that will bring us the highest quality results.

We know that for The Charity to have the biggest impact we must embrace new ideas and invest in beginnings that will create a better future. Our work must be bold and inspiring. It must set us apart.

To reflect this, we've included our own unique brand of coffee, generously provided by expert coffee roasters 200 Degrees, with your annual report

We hope that, as you enjoy a cup whilst reading the report, you'll get a taste of how we are bringing about global collaboration to speed up discoveries.

We hope that you'll drink in a little of how our support work is improving the day-to-day quality of life for everyone impacted by the disease.

But above all, we hope that you'll take away a taste of the passion, energy and inspirational nature of our incredible community, and that a part of this stays with you forever.

Sarah Lindsay

CEO, The Brain Tumour Charity

Our vision

Our vision is for a world where brain tumours are defeated.

Our goals

1. Double Survival by 2025
2. Halve the harm that brain tumours have on quality of life by 2020

Our values

Our values underpin our culture, the way we do things and what we believe in. We are pioneering, passionate, collaborative and smart.

A Cure Can't Wait

Scaling new heights



As part of our strategy, *Defeating Brain Tumours*, we're committed to halving the harm that brain tumours have on quality of life. To do this, we know that we must act innovatively and not be afraid to invest in pioneering research in order to scale new heights.

This is why we're proud to have awarded £5 million to Dr David Jones to set up The Everest Centre for Research into Paediatric Low Grade Brain Tumours.

The centre, to be led from Heidelberg, Germany, will bring together the field's most prestigious scientists, from Germany and the UK, who will work to increase our understanding of the disease biology and make ground-breaking discoveries in identifying new treatment options.

This crucial research will enable us to positively impact the

everyday lives of children and young people living with low grade tumours and has only been possible thanks to the phenomenal efforts of our trustee, Rob Ritchie. Rob, whose son Toby was diagnosed with a low grade brain tumour aged five, raised £3 million by skiing uphill 8,484 metres in the Swiss Alps (the same height as Everest) with a team of 13 others in order to help fund the centre.

"By establishing The Everest Centre, The Brain Tumour Charity is accelerating progress towards finding more effective treatments for paediatric patients living with low grade tumours. The difference this could make to the children facing this devastating disease day in and day out, could be huge."

Trustee, Rob Ritchie.

Encouraging innovation

£6.85m – The amount we've committed to scientific, clinical and quality of life research this year.

Last autumn, we announced that, as part of our Quality of Life Awards, we would be funding three exciting research initiatives which would focus on reducing the burden and harm to those diagnosed with a brain tumour.

More recently, we've also awarded over £700k to eight cutting-edge research projects across the globe, including in Canada, Australia and the UK, as part of our New Ideas Awards.

These initiatives, alongside the others we've funded, reflect the pioneering and bold nature of our research which we believe will help propel us more quickly towards our vision: a world where brain tumours are defeated.

thebraintumourcharity.org/new-ideas

Ensuring high quality research

As we work to speed up the time it takes to turn discoveries into treatments and cures, it's crucial that The Charity still funds only the highest quality research.

To ensure this, we've formed two Scientific Advisory Boards (SABs) which are made up of internationally renowned scientific and medical experts that work in different areas of cancer research and social science. The Biomedical SAB, chaired by Professor Richard Gilbertson, and Quality of Life SAB, chaired by Dr Antony Michalski, are responsible for the assessment and rating of applications for research funding and making recommendations to our Board of Trustees. They also include lay representatives who are an integral part of the SABs and provide a valuable perspective as experts through experience.

We know that exceptional results can only come from exceptional research. Our SABs are vital in shaping this journey.

Investing in a better future for patients

While survival has doubled across all cancers, survival rates for adults with brain tumours have improved little in over 40 years.

In order to change this, we know that we must think differently, not be afraid to take calculated risks and embrace bold new beginnings.

We've therefore taken the ground-breaking decision to establish The Brain Tumour Fund, a first-of-its-kind, brain-tumour-focused venture philanthropy fund.

The Brain Tumour Fund, which is targeting £40 million in capital commitments, will invest in companies with products or platform technologies that have the potential to improve the survival of brain tumour patients or to reduce the debilitating effects of the disease.

As a cornerstone investor, we've pledged £10 million to kick-start the fund and believe that by attracting major investors into the field of neuro-oncology research to also invest, we can drive forward the development of new therapies and speed up progress towards a cure.

thebraintumourcharity.org/brain-tumour-fund



£34.1 MILLION

THE AMOUNT WE'VE
COMMITTED TO
PIONEERING RESEARCH
INTO BRAIN TUMOURS TO
DATE.

Every Patient is a Research Patient

Providing a digital platform for patients



Improving life for our community and accelerating our quest to find a cure is at the heart of everything that we do.

This is why, over the year, we began developing one of our most exciting, revolutionary initiatives to date – a global, patient-led data bank.

The data bank will provide a digital platform where medical and quality of life information can be shared openly with both patients and researchers. This innovative resource will enable patients to share their data to help accelerate the progress of vital research and new treatments, as well as empowering them to make better informed decisions about their own treatment plans.

Our aim is for the data bank to help patients, clinicians and scientists collaborate for better health outcomes. This will be a crucial step in our quest to ensure that every patient who wants to contribute to research is able to and, going forward, could radically change the current research landscape.

Helping to shape research



The views of those affected by brain tumours are vital to researchers when shaping programmes of research. This ensures that their work remains relevant and reflects the needs of our community.

Since we launched our Research Involvement Network (RIN), to drive collaboration between researchers and patients, it has gained 85 members who, last year alone, were involved in an incredible 34 research projects.

By sharing their experiences, those living with a brain tumour, those who've lost someone to a brain tumour or those who are currently caring for a loved one with a brain tumour, have

brought a wealth of information to the network. This insight has been invaluable in helping researchers to gain new perspectives on their work.

"It was great to be involved in this group, for our experiences to be useful and to feel like we were giving something back."

Deborah, whose daughter was diagnosed with a brain tumour aged three.

ONLY 3% OF BRAIN TUMOUR
PATIENTS ARE CURRENTLY ENROLLED
IN CLINICAL TRIALS, DESPITE MANY
MORE WANTING THE OPPORTUNITY.

Early and Accurate Diagnosis

Driving down diagnosis times

Since we launched our award-winning HeadSmart campaign, we've helped drive down average childhood brain tumour diagnosis times from 13 weeks to 6.5.

Determined to get this reduced to four weeks, over the last year we've relaunched the campaign. Following a clinical evidence review, led by the Children's Brain Tumour Research Centre at The University of Nottingham, one of the partners involved in HeadSmart, we updated the common signs and symptoms of a brain tumour in children and teenagers so that HeadSmart remains a respected resource for GPs and other healthcare professionals.

We also refreshed the brand identity, created a new website and developed an animation for the campaign to better engage key audiences and, in particular, stand out to teenagers who on average take longer to be diagnosed than babies and children.

Finally, as part of the exciting refocus, we introduced an eye-catching campaign icon called Sam - named after Samantha Dickson, who sadly passed away from a brain tumour when she was just 16. Samantha's parents, Neil and Angela Dickson, are one of our founders and were instrumental in establishing our HeadSmart campaign.

The awareness raised by relaunching the campaign will be crucial in making sure that brain tumours are diagnosed and treated much earlier.

[Headsmart.org.uk/sam-animation](https://headsmart.org.uk/sam-animation)

HeadSmart is funded and promoted by The Brain Tumour Charity and run in partnership with the Children's Brain Tumour Research Centre (CBTRC) and the Royal College of Paediatrics and Child Health (RCPCH).

Improving the accuracy of diagnoses

Improving the accuracy of brain tumour diagnoses means those affected could receive more effective treatments.

This is why, last December, we launched a funding call for our Clinical Biomarkers Awards.

Biomarkers are biological markers, or indicators, such as a molecule or gene, that can be used to help diagnose the type of brain tumour a patient has and how best to treat it.

By providing grants to researchers to focus on the discovery of these biomarkers, our hope is that their findings will bring us closer to earlier and more accurate diagnoses of brain tumours, drastically improving outcomes for patients.



2.7 MILLION

THE NUMBER OF HEADSMART
SYMPTOM CARDS WE'VE DISTRIBUTED
TO DATE.

Equal Access to the Best Treatment

Empowering our community

"If the Patient Guide had been around when Dad was diagnosed, I believe that we'd have been able to get more information from health professionals, more support and ultimately more precious time to spend with him."
Jayne Wilson who lost her father, Hayden, to a brain tumour.



From our report, *Finding Myself in Your Hands: The Reality of Brain Tumour Treatment and Care*, we found that nearly three out of 10 patients currently receiving treatment were not given a choice of relevant treatment options. In a recent survey, we also discovered that two thirds of people living with a brain tumour were not signposted to suitable support.

In order to take a vital step towards changing this, last November we were proud to launch our new *Patient Guide to Brain Tumour Treatment and Services for Adults*.

The guide, which has already been accessed by over 2,000 patients, includes our patient pathway which outlines the standard of care that we believe all adults living with a brain tumour should expect to receive from the NHS. It also offers information on clinical trials and research opportunities that are not routinely offered to all patients at this time.

We believe that this powerful resource will play a crucial role in empowering patients to confidently navigate the system and in ensuring that every person with a brain tumour has equal access to the best treatment and care.

thebraintumourcharity.org/patient-guide


Using our voice as a catalyst for change

Over the last year, our Policy and Public Affairs team have successfully influenced decision makers and organisations on a range of important issues that directly affect our community.

Highlights include lobbying NHS England to include brain tumours in their research around patient access to a clinical nurse specialist (CNS), getting a motion tabled in the Scottish Parliament on the relaunch of the HeadSmart campaign, which was signed by 46 MSPs and briefing the DVLA, leading to the agency making the process by which they make decisions about an individual's ability to drive more transparent.

Evidence from The Brain Tumour Charity was cited on a number of occasions in the 'House of Lords Select Committee on Charities' report, "Stronger Charities for a Stronger Society," published in March 2017. The Committee commented on our remarks regarding the impact of Brexit, volunteering, charity mergers, the Lobbying Act and the use of digital technology.

We have also played a key role in advising the Department of Health and other members of the Government's Task and Finish Group on what the current barriers to research into brain tumours are and have continued to lead on the discussions for change.



CURRENTLY ONLY 1.9% OF NATIONAL
CANCER RESEARCH FUNDING IS
ALLOCATED TO RESEARCH INTO BRAIN
TUMOURS.

Improving Life Today

Putting the right support in place



In February, we were thrilled to award funding for our first low grade tumour clinical nurse specialist at King's College Hospital. Having access to a clinical nurse specialist (CNS) makes a significant difference to an individual's experience of symptom burden, access to information and, emotional and mental health. By funding this vital post, we can improve life today for patients and help to manage the impact that their brain tumour has on their health and wellbeing. Our goal is to be funding 25 CNSs by 2020.

"We feel extremely excited to be working with The Brain Tumour Charity on this service. Having a CNS recruited specifically to look after low grade brain

tumour patients will mean that there is a consistent and knowledgeable point of contact who will be able to support and assist those affected throughout."

Jen Watson, Director of Nursing, King's College Hospital, London.

Raising vital awareness

'Loss of vision meant she often felt lonely at first as she couldn't find her friends in the playground.'
Parent, daughter aged 7 with a high grade tumour.

Last June, following our survey of the experiences of 300 young people and parents on what life is like after a brain tumour diagnosis, we published our report, *Losing My Place: The Reality of Childhood with a Brain Tumour*. This research, which is the most comprehensive study of its kind, found that brain tumours interrupt the natural process of growing capacity and independence from parental care in ways no one involved can prepare for. The report received national media coverage and will be used to help us ensure policy makers, healthcare professionals and the public understand the realities for a young person living with a brain tumour.

Building lasting connections



Throughout the year we held a series of Family Days across the UK, some of which were generously funded by The Lewis Moody Foundation and BBC Children in Need.

In total, we were delighted to welcome over 100 families who took part in a range of exciting activities.

These events provided an invaluable opportunity for children or parents diagnosed with a brain tumour, and their families, to have some respite from their worries and some much-needed time and fun together.

Most importantly, the days allowed parents and children alike to meet others in a similar situation and make real, long-lasting connections. The comfort and strength families draw from experiences like these is immeasurable.

Offering financial guidance

£420,000 – The estimated total amount that the Benefits Clinic has helped families start making claims for.

Last April, we partnered with Citizens Advice Rushmoor to launch our very own Benefits Clinic to ensure that families affected by a brain tumour diagnosis were not having to face further worry and stress during an already difficult time.

Since setting up the clinic, on average, each person that the service has helped is nearly £5,000 better off, with some families set to be as much as £10,000 better off over a 12 month period.

The service has helped a large number of families across the UK on a wide range of money issues. It has empowered our community to ask for what they're entitled to and, in one case, helped an individual to avoid homelessness.

Improving best practice



We've always recognised that in order to best support those living with a brain tumour, we must also support the professionals involved in their care.

This is why, last May, we decided to hold our first ever Nurse and AHP study day for nurses and allied health professionals working with adults with a brain tumour.

The event, which was attended by over 160 delegates, provided a unique opportunity for individuals to network, hear from knowledgeable speakers and share best practice across the sector. Following the day, over 99% of the attendees rated the quality of the education they'd received as good or excellent.

Offering parents new promise

We were the leading sponsors of the International Symposium on Pediatric Neuro-Oncology (ISPNO) in Liverpool last June. As part of this global event, which brought over 1,100 international academics and clinicians together, we were thrilled to host our third Paediatric Brain Tumour Information Day for families.

Speakers included world-leading experts, Dr Mark W. Kieran (Boston, USA) and Dr Roger J. Packer (Washington, USA) who, alongside other internationally renowned researchers and individuals personally affected by a brain tumour, delivered highly inspiring and informative talks.

In total, more than 90 people attended the day and, thanks to all our excellent speakers, families left the event feeling better informed, less isolated and more in control of the complex issues that they face on a daily basis.

bit.ly/NPIDVideos

Growing our support services for families

During 2016/2017, we were delighted to be awarded grants by BBC Children in Need and St. James's Place Foundation.

Together, these combined donations, amounting to over £200,000, will help to fund our crucial Children and Families Service which provides families with support and information when they need it most. These incredibly generous contributions will be instrumental in enabling us to provide a Children and Families Worker who can offer vital one-to-one support for families, Paediatric Information Days, Family Days, Brainy Bags and our education packs for teachers – for the next three years.

The funding from St. James's Place was inspired by Alex Bolt, who died from a brain tumour at the age of just 16.

United in Our Battle to Defeat Brain Tumours

A united sea of red



Over 1,800 - The number of people who took part in The Twilight Walk.

Over £280,000 - The amount raised to support our vital work.

Last October, The Twilight Walk brought together over 1,800 passionate people, including volunteers, as they united to stamp out brain tumours for good. This is a 50% increase on the previous year, making the walks in Warwick, Chester and Windsor the largest to date. The huge event saw walkers of all ages, whose lives have been touched by a brain tumour,

completing the 10k routes in order to raise crucial funds for the 102,000 people currently living with a brain tumour in the UK.

"Seeing a sea of red is so touching and it's amazing how powerful hundreds of strangers sharing the same purpose can be." Tracey.

The strength of our supporters

"I am completely lost without Michael, but I know he wouldn't want me to give up. Setting up a Supporter Group fund to try and help others facing the same fight is a huge part of that, and something I know Michael would have completely supported."

Lucy Barry, who lost her husband Michael to a brain tumour.

Our Supporter Groups are devoted groups of friends, families and colleagues who come together to fundraise in memory of, or inspired by, a loved one in order to raise money and awareness for The Brain Tumour Charity. In 2016/2017 they generated an astounding income of over £930,000*, which will be invaluable for our work. Over the year we have been honoured to welcome another 25 Supporter Groups, growing this inspiring community to 277 groups in total now.

*[*This figure includes all money raised directly by Supporter Groups excluding that generated by individuals associated with Supporter Groups in events such as the Virgin Money London Marathon.]*

The perfect blend of #TheBrainyBunch



Once again #TheBrainyBunch left us in awe of their incredible efforts, energy and drive as they continued to fundraise tirelessly for us throughout the year.

Thousands of our dedicated community got involved in a wide range of events and challenges including runs, cycles, swims, rows, skydives, bake sales, car boot sales, raffles and balls.

In April, 101 runners took part in The Virgin Money London Marathon 2016 on our behalf. They raised over £248,000 for The Charity and gained excellent local and national media coverage, enhancing vital awareness of our cause.

A burst of bandana energy

Over £100K – The amount we raised towards our research.

On 3 March, thousands of our community united with passion and energy to #WearItOut for Brain Tumour Awareness Month.

Across the country our wonderful supporters came together to hold a range of exciting events including bake sales, sponsored swims, dress down days and cycles, in order to fund 400 days of vital research into brain tumours.

BAFTA-award winning actress, Olivia Colman got in on the act too, enthusiastically donning a bandana to show her support.

We are really grateful to all involved. Your fantastic efforts enabled us to generate a 34% increase on the total we raised the previous year. All the vital money and awareness raised will continue to move us closer towards our twin goals of doubling brain tumour survival and halving the harm caused by the disease.

A review from Professor Keyoumars Ashkan



As a neurosurgeon, I'm reminded daily of the vital need for groundbreaking, new treatments for brain tumours.

I'm therefore proud to support The Brain Tumour Charity and the inspiring progress that it has made throughout 2016/2017.

The Charity's commitment to funding the most effective, outcomes-orientated research is unfaltering and every page of this report reflects its determination and pioneering vision in doing so.

Major milestones during the year that have stood out to me include The Charity's work on the global, patient-led data bank, which could revolutionise the development of new treatments and its investment into the venture philanthropy fund, an important move to stimulate further research into

this cruel disease.

To accelerate the time it takes to turn lab discoveries into treatments, it's imperative that investments are made in a wide range of innovative projects. It's great to see that The Charity has awarded funding to several new research initiatives over the last year.

It's vital work like this that continues to move The Charity closer to unlocking potential treatments and closer to finding a cure.

**Professor Keyoumars Ashkan,
Professor of Neurosurgery, Kings College, London**

Thanks

Last year The Charity continued to fund the highest quality research, and support thousands of people affected by a brain tumour. This work is only possible due to our dedicated supporters and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us. To everyone involved, we cannot thank you enough.

Trusts

BBC Children in Need
The Colin Oliphant Charitable Trust
F J Wallis Charitable Settlement
Halifax Foundation for Northern Ireland
The Hugh Fraser Foundation
Souter Charitable Trust

Stay Strong Stu
St James's Place Foundation
The Ed Evans Foundation
The Sir James Reckitt Charity
William Brake Charitable Trust

Corporates

ASCO
Audit Scotland
Avaya
Aykroyd & Sons
Betterware Limited
BGC Partners – BGC Charity Day
Bluecube Technology Solutions
Carbon Clear
Chiltern Railways
Cisco
Diageo
DWF LLP
Edinburgh Woollen Mill
Enquest
Evolution Coaching
Floor & Wall Ltd
GE Healthcare
Goldman Sachs

Hewlett-Packard
IBM
Ipreo
Lockton Companies LLP
London & Partners
Macfarlanes LLP
Martin Brokers
Michelmores LLP
Moneycorp
Parker Design
RBC Global Asset Management
Resolute
St Andrews Charity Fashion Show
Tesco Express
UPS
Voip Unlimited
Waitrose

Co-funding Partners

Action Medical Research
Cancer Research UK
Children with Cancer UK
Great Ormond Street Hospital Children's Charity

The Medical Research Council
OSCAR'S Paediatric Brain Tumour Charity
Stay Strong Stu

High profile supporters

Alastair Stewart OBE
Caroline Lucas MP
Chris White former MP
Dillon St.Paul
Dr Chris Jones
Dr Colin Watts
Dr Paul Brennan
Emma McClarkin MEP
Greg James

Lorraine Kelly OBE
Marc Silk
Councillor Margaret Rose
Matt Allwright
Mel Giedroyc
Olivia Colman
Owain Arthur
Professor Barry Pizer
Professor Denise Sheer

Guy Opperman MP
Hal Cruttenden
Holly Matthews
Jack Morris
Jason Durr
John Maynard
Jonny Wilkinson CBE
Professor Keyoumars Ashkan
Lewis Moody MBE

Professor Susan Short
Rob Ritchie
Sarah and Ben Pullen
Steve Backshall
Dr Steve Pollard
Tcheky Karyo
Tim Burgess and The Charlatans
Tom Daley

Trustees and Governance

Trustees

Sir Martin Narey (Chair)
Neil Dickson MBE (Vice Chair)
Graham Lindsay (Vice Chair)
Tim Burchell
Angela Deacon
Angela Dickson MBE
Andy Foote
Simon Hay

Nigel McGinnity
Justine McIlroy (*appointed January 2017*)
Philippa Murray
Berendina Jill Norton
Graham Norton
Professor Alan Palmer (*appointed July 2016*)
Robert Posner
Rob Ritchie (*appointed April 2017*)

President

Professor Sir Colin Blakemore

Chief Executive Officer

Sarah Lindsell

Company Secretary

Angela Deacon

Registered Charity Number (England and Wales): 1150054

Registered Charity Number (Scotland): SC045081

Registered Company Number: 08266522

Registered office

Hartshead House
61-65 Victoria Road
Farnborough
Hampshire
GU14 7PA

Auditors

Menzies LLP
Victoria House
50-58 Victoria Rd
Farnborough
GU14 7PG

Bankers

Lloyds Bank Plc
PO Box 1000
Andover
BX1 1LT

Legal Advisors

Bates Wells Braithwaite LLP
Scandinavian House
2-6 Canon Street
London
EC4M 6YH

Governance

Biomedical Scientific Advisory Board (Biomed SAB)

Name

Professor Richard Gilbertson MBBS, PhD (*Chair*)
Dr Mark Gilbert MD (*Vice Chair*)

Dr David Adams PhD
Dr Kenneth Aldape MD
Professor Robert Brown PhD

Dr Susan Chang MD
Dr Eyal Gottlieb PhD
Dr Paul Northcott PhD
Professor Nicola Sibson PhD

Professor Martin van den Bent MD, PhD
Dr Ian Waddell PhD

Institution

The Cambridge Cancer Centre
The Centre for Cancer Research at the National Cancer Institute, USA
The Wellcome Trust Sanger Institute
The University of Toronto, Canada
Imperial College London and The Institute of Cancer Research
The University of California, San Francisco, USA
The Technion Institute of Technology, Israel
St. Jude Children's Research Hospital, USA
The CRUK/MRC Oxford Institute for Radiation Oncology
Erasmus University, The Netherlands
The Cancer Research UK Manchester Institute

Quality of Life Scientific Advisory Board (QoL SAB)

Name

Dr Antony Michalski MB ChB, MRCP, PhD, FRCPCH (*Chair*)
Professor Martin Taphoorn MD, PhD (*Vice Chair*)
Professor Terri Armstrong PhD, ANP-BC, FAANP
Dr Paul Brennan MB, BChir MRCS (Ed), PhD
Dr Rachel Cox MB, ChB, MRCP MA MD
Professor Filomena Maggino PhD
Dr Diane Puccetti MD
Professor Maggie Watson PhD, Dip.C.Psych, AFBPS

Institution

Great Ormond Street Hospital

The VU University Medical Center, Amsterdam

The National Institute of Health, USA
The University of Edinburgh
University Hospitals Bristol
Sapienza University of Rome, Italy
The University of Wisconsin
The Royal Marsden Hospital and University College London

Lay Advisors

Deborah Crossan
Christina Brincat
Professor Celine Boehm
Louise Edwards
Rachel Rathbone

Last but not least...

We'd like to say a huge thank you to Tom Vincent, Rob Darby, Matt Shelton, Tim Moss and everyone at 200 Degrees Coffee for all their support over the year and for creating and donating this delicious, *Brain Tumour Charity Blend*, coffee to help us provide you with a taste of our work.

Objectives for 2017 - 2018

The Charity continues to grow and deliver successfully on its charitable objectives, building on its position as the largest dedicated funder of research into brain tumours in the UK to become the leader in this field globally.

We have referred to the guidance in the Charity Commission's general guidance on public benefit when reviewing our objectives and in planning our future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

The goals for 2017/18 have been set, maintaining our commitment to our long-term strategic objectives and in line with our five year strategy:

1. Fund our current research commitments including programme grants, research projects, clinical trials and clinical fellowships.
2. Launch new awards for funding research in: Expanding Theories; Quality of Life; Clinical Biomarkers; Quest for Cures; and Future Leaders.
3. Initiate the development of a brain tumour databank to revolutionise the availability and use of brain tumour data worldwide.
4. Fund new clinical fellowships and clinical trials through our strategic partnerships with the Medical Research Council and Cancer Research UK.
5. Publish our research impact report on the progress we are making against our goals.
6. Establish our Patient Guide as an optimal practice standard for brain tumour treatment and care.
7. Build our funding of CNS posts in NHS hospitals, to improve experiences for brain tumour patients.
8. Continue to expand our Support & Information Service by developing new and stronger partnerships with healthcare professionals and other service providers.
9. Develop a campaign for earlier diagnosis in adults, based on the findings from our new research project.
10. Create a bespoke HeadSmart campaign for a teenage audience and look at the evidence to support a similar adult early diagnosis campaign.
11. Widen our digital reach to increase awareness of brain tumours and access to our services, particularly amongst the newly diagnosed.
12. Further diversify our income streams through corporate partnerships, trading, legacies, regular giving and events that also unite the brain tumour community.

Structure, governance and management

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum and articles of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition consideration is given to whether there is a need for any specific community or stakeholder group that needs to be "represented" by a new trustee. The Board operates an equal opportunities recruitment policy and trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review. Induction papers covering the role and responsibilities of trustees are provided to the trustees and governance updates are provided as and when appropriate. The trustees who served during the year are listed above.

The trustees meet four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All trustees give of their time freely and no trustee remuneration was paid in the year. Details of trustee expenses are disclosed in Note 9 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the trustees on performance and operations.

The Charity benefits from four sub-committees which have been established to advise on key areas of activity, which are:

- Finance Sub-Committee
- Research Sub-Committee
- Information and Support Sub-Committee

- Remuneration Sub-Committee

As described previously in this report, The Charity has formed two Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. Further details of the Biomedical Scientific Advisory Board (Biomed SAB) and the Quality of Life Scientific Advisory Board (QoL SAB) can be found on page 14, set out under 'Governance'.

Accreditations

The Charity is a longstanding member of the Association of Medical Research Charities (AMRC). The AMRC is an umbrella organisation of the leading medical and health research charities in the UK. The Charity aims to follow the highest standards of accountability in medical and health research funding, and membership of AMRC requires the use of independent peer review in the allocation of all grants and awards for research. The Charity has twice received a best practice award for its peer review process.

The Charity has again been awarded The Information Standard and is a member of The Helplines Partnership. The Charity is a member of the Fundraising Standards Board, adhering to its best practice guidelines. It is represented on a number of influential bodies and cancer campaigning groups.

Grant-making Policy

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

Almost 11,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40. There are thousands of people who are diagnosed with a secondary brain tumour, when the cancer has spread from another part of their body. The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We believe that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. The Charity is a member of the Association of Medical Research Charities and seeks to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Sub-Committee and our Grant Review and Monitoring Committee, supported by the Research Team. In all cases, continuation of funding is subject to the research undertaken being in the interests of The Charity and a progress assessment that is satisfactory.

Finance review

Last year, The Charity's underlying ordinary income, which excludes exceptional income, was £7,382,114, so we're delighted to see this figure rise to £8,600,686 for 2016/2017 – an increase of 17%.

We're also pleased to see that the income from individual giving has hugely increased from the previous year, jumping 32% to £666,575 from £505,179.


All of our services are free of charge for anyone whose life has been affected by a brain tumour. This, coupled with our research and awareness work, is only possible thanks to our dedicated supporters, as we receive no Government or statutory funding and rely 100% on voluntary funding.

Income

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This is a good position to be in, in an uncertain climate.

After taking out the exceptional income of £2.9m in 2015/16 we have seen a growth of 17% on the prior year to £8,600,686. (2015/16 £7,382,114). We saw a leap in legacy income which achieved £1,072,290 up from £311,971. There has also been good growth from major donors, supporter groups, and individual giving. Our flagship event, The Twilight Walk, was a great success raising year over £280k against £221k in the prior year. Our corporate partnership with Lockton LLP was our most successful one year partnership to date raising over £170k.

Overall this is a good result given that growth generally in the sector has slowed over the last two years and this is likely to continue. Fundraising income for the top 100 charities grew by 2.3% in the same period, well under half of last year's growth rate, and the lowest rate for six years (*ref: Centre for Giving and Philanthropy @Cass Business School*)




Expenditure

Total expenditure increased £1,463,284 in the year to £7,988,539.

Expenditure on our charitable activities increased by £1,306,334 in the year to £6,328,961, underpinned by a further significant increase in research spend. Further information about our achievements in the year are set out elsewhere in this report. The Charity has a target of maintaining its cost of raising funds at less than 20p for each £1.00 of income. During the year we spent less than 19p for each £1.00 raised and each £1.00 invested in fundraising generated £5.18 in income.

The Charity has one subsidiary, TBTC Trading Limited. The subsidiary, which is wholly owned, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Limited made a profit of £15,354 which will be donated to The Charity.



Reserves policy

The reserves policy of The Charity is to maintain unrestricted funds of at least six months operational costs to ensure the long-term sustainability of our services for our beneficiaries and to support our research commitments, which is on average £3,495,165. The level of free reserves at 31 March 2017 were £5,609,494, made up of total reserves less restricted funds, designated funds and net book value of fixed assets (2016 - £3,006,141). At 31 March 2017 we had unaccrued but committed research expenditure totalling £8,694,640 that was subject to satisfying ongoing monitoring requirements. After the year-end The Charity continued to expand its research activities, awarding a further six grants representing a total additional commitment of £4.1m. Accordingly, at the time of issuing this report The Charity has combined unaccrued commitments of some £12.8m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent, these preferences usually include our research or support activities. Income raised by these Supporter Groups is designated by the trustees for the activities identified by each group. In addition, the trustees approved funding of a Chair position at a UK university, funds to cover this position have been classed as designated.

From time to time The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Sub-Committee meets on a quarterly basis to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

Investment policy

The investment of funds is controlled by the trustees who have appointed The Charity's Finance Sub-Committee to implement the trustees' investment decisions. Albert E Sharp has been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with Albert E Sharp is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. In reaching investment decisions, the trustees consider the cash position of The Charity and our projected short and medium term cash needs. Albert E Sharp's performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end The Charity had a £10.2m portfolio of UK equities, fixed interest securities and cash, managed by Albert E Sharp. In a volatile year for investments the portfolio generated income of £252,770 and generated a valuation gain of £1,186,512. At the year end the accumulated unrealised gain on the portfolio of £937,783.

After the year end The Charity's Finance Sub-Committee appointed Smith & Williamson as a second investment manager, alongside Albert E Sharp. Smith & Williamson are managing £2.0m of The Charity's funds, the investment mandate Smith & Williamson are following is the same as that agreed with Albert E Sharp.

Employees

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing the charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

Risk factors

The trustees have considered the major risks to which The Charity is exposed and have reviewed those risks and established systems and procedures to manage them. The Finance Sub-Committee reviews governance and risk during each year and makes recommendations on best practice to the trustees. The principal risks and uncertainties facing The Charity and how we endeavour to mitigate these are:

- We fail to secure adequate income. We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts.
- We are not able to commission enough high quality research projects. We are developing our engagement with the brain tumour research community and working to build capacity in the sector and we are looking at alternative research models. In addition we have extended funding through building relationships globally.
- We become affected by damage to our reputation or negative sentiment in the charity sector. We manage reputation risk through staff training and effective HR and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.
- Our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.

Public benefit statement

The Brain Tumour Charity provides public benefit as a charity by:

- Supporting research into the nature, causes, diagnosis and treatment and social consequences of brain tumours.
- Relieving the suffering of people with brain tumours and their families and carers.
- Raising awareness and advancing public education in all areas relating to brain tumours.

The trustees have considered the Charity Commission's general guidance on public benefit and have taken it into account when reviewing The Charity's aims and objectives and in planning its future activities. The trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

Going concern

The trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks, and consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

Statement of the trustees' responsibilities

The trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure, of the Group for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The financial statements were approved and authorised for issue by the trustees on 8 November 2017 and signed on their behalf by:

Sir Martin Narey
Chair of Trustees

Independent auditor's report

We have audited the financial statements of The Brain Tumour Charity for the year ended 31 March 2017 which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the charitable company's trustees, as a body, in accordance with section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinion we have formed.

Respective responsibilities of trustees and auditor

As explained more fully in the Trustees' Responsibilities Statement in the Trustees' Report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the APB's website at www.frc.org.uk/apb/scope/private.cfm.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 March 2017 and of the group's and the parent charitable company's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Trustees' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements and such reports have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records or returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the trustees' Report.

Malcolm Lucas FCA (Senior Statutory Auditor)
For and on behalf of MENZIES LLP
Chartered Accountants and Statutory Auditor

Victoria House
50 - 58 Victoria Road
Farnborough
Hampshire
GU14 7PG

Date: 13 November 2017

Consolidated Statement of Financial Activities for the year ended 31 March 2017

	Notes	Unrestricted Funds £	Restricted Funds £	Total 2017 £	Total 2016 £
<u>Income and Expenditure</u>					
Income from:					
Donations and legacies	3	6,318,658	878,920	7,197,578	5,940,835
Charitable activities	4	4,228	230,003	234,231	201,928
Other trading		666,399	250,521	916,920	1,022,039
Investments		251,957	-	251,957	217,312
Ordinary income		7,241,242	1,359,444	8,600,686	7,382,114
Exceptional income	5	-	-	-	2,889,949
Total income		7,241,242	1,359,444	8,600,686	10,272,063
Expenditure on:					
Raising funds		1,600,779	58,799	1,659,578	1,502,628
Charitable activities					
Research		2,157,074	2,029,296	4,186,370	3,175,511
Patient Support		897,778	179,302	1,077,080	795,670
Campaigning and raising awareness		900,686	164,825	1,065,511	1,051,446
Total expenditure on charitable activities		3,955,538	2,373,423	6,328,961	5,022,627
Total expenditure	6	5,556,317	2,432,222	7,988,539	6,525,255
Net income before gains and losses on investment assets		1,684,925	(1,072,778)	612,147	3,746,808
Realised and unrealised (loss)/gains on investment assets		1,219,913	-	1,219,913	(349,194)
Net income/(expenditure) and net movement in funds for the year		2,904,838	(1,072,778)	1,832,060	3,397,614
Reconciliation of Funds					
Balances at 1 April 2016		6,343,710	3,816,391	10,160,101	6,762,487
Balances at 31 March 2017		9,248,548	2,743,613	11,992,161	10,160,101

The Statement of Financial Activities includes all gains and losses recognised in the year.
All incoming resources and resources expended derive from continuing activities.
The notes on pages 26 to 38 form part of these financial statements.

Consolidated Balance Sheet at 31 March 2017

Company number: 08266522

	Notes	Consolidated 2017 £	2016 £	Company 2017	2016 £
Fixed Assets					
Intangible assets	13	88,633	48,711	88,633	48,711
Tangible assets	14	68,193	81,106	68,193	81,106
Investment in subsidiary	15	-	-	100	100
Investments	16	10,213,141	8,959,443	10,213,141	8,959,443
Current Assets					
Stock		7,797	10,513	-	-
Debtors	17	1,044,048	438,866	1,036,548	431,327
Cash at bank		7,447,408	5,317,666	7,445,879	5,325,141
		<u>8,499,253</u>	<u>5,767,045</u>	<u>8,482,427</u>	<u>5,756,468</u>
Creditors:					
Amounts falling due within one year	18	(6,877,059)	(4,696,204)	(6,875,687)	(4,709,340)
Net Current Assets		<u>1,622,194</u>	<u>1,070,841</u>	<u>1,606,740</u>	<u>1,047,128</u>
Total assets less current liabilities		<u>11,992,161</u>	<u>10,160,101</u>	<u>11,976,807</u>	<u>10,136,488</u>
Funds	22				
General reserve		5,766,320	3,135,958	5,750,966	3,112,345
Designated funds		3,482,228	3,207,752	3,482,228	3,207,752
Unrestricted funds		<u>9,248,548</u>	<u>6,343,710</u>	<u>9,233,194</u>	<u>6,320,097</u>
Restricted funds		<u>2,743,613</u>	<u>3,816,391</u>	<u>2,743,613</u>	<u>3,816,391</u>
		<u>11,992,161</u>	<u>10,160,101</u>	<u>11,976,807</u>	<u>10,136,488</u>

The financial statements were approved by the trustees on 8 November 2017 and signed on their behalf by:

.....
Sir Martin Narey
Chair of Trustees

.....
Neil Dickson MBE
Vice-Chair of Trustees

The notes on pages 26 to 38 form part of these financial statements.

Consolidated Cash Flow for the year ended 31 March 2017

	Total 2017 £	Total 2016 £
<u>Reconciliation of net income to net cash flow from operating activities</u>		
Net income for the year	1,832,060	3,397,614
Adjustments for:		
Depreciation charges	45,157	24,550
(Gains)/losses on investments	(1,219,913)	349,194
Dividends, interest and rents from investments	(251,957)	(217,312)
Decrease in stocks	2,716	4,011
Increase in debtors	(604,158)	(5,208)
Increase in creditors	2,203,185	1,493,209
Net cash provided by (used in) operating activities	2,007,090	5,046,058

	Total 2017 £	Total 2016 £
<u>Statement of cash flows</u>		
Cash flows from operating activities		
Net cash provided by (used in) operating activities	2,007,090	5,046,058
Cash flows from investing activities:		
Dividends, interest and rents from investments	217,148	212,284
Purchase of computer software	(77,019)	-
Purchase of property, plant and equipment	(17,477)	(65,268)
Purchase of investments	-	(2,949,554)
Net cash used in investing activities	122,652	(2,802,538)
Change in cash and cash equivalents in the year	2,129,742	2,243,520
Cash and cash equivalents at 1 April 2016	5,317,666	3,074,146
Cash and cash equivalents at 31 March 2017	7,447,408	5,317,666

Notes to the Financial Statements

1. Statement of compliance

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2016) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 13. The principal activity of the company and the nature of its operations are set out in the trustees report on page two.

2. Accounting Policies

(a) Basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102. The financial statements are prepared in sterling, which is the functional currency of the entity. The results and balance sheet of The Charity’s subsidiary undertaking, TBTC Trading Ltd has been consolidated on a line by line basis. TBTC Trading Ltd prepares its accounts to 31 March.

A separate statement of financial activities has not been presented for The Charity alone as this is not considered to be materially different from the consolidated statement of financial activities (“SOFA”). The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2016) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and Companies Act 2006. The Brain Tumour Charity meets the definition of a public benefit entity under FRS 102.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy, management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows.

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) **Company status**

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 13. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

(c) **Income**

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest is accounted for on an accruals basis.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) **Expenditure**

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

(e) **Stocks**

Stock is measured at the lower of cost and net realisable value.

(f) **Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) **Fixed assets**

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £500 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) **Estimated useful lives**

The estimated useful lives of fixed assets are as follows:

Computer equipment	Three years
Office equipment	Five years
Leasehold improvements	The lease term
Computer software	Five years

(i) **Investments**

Investments are revalued at market value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) **Donated Assets and Services**

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) **Operating lease**

The Charity classifies the lease of Hartshead House as an operating lease. Rental charges are provided over the term of the lease (five years).

(l) **Pensions**

The charitable company operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independent of the charitable company's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) **Financial instruments**

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) **Going concern**

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees. The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

3. Donations and legacies

	Unrestricted £	Restricted £	2017 Total £	Unrestricted £	Restricted £	2016 Total £
Ordinary activities:						
Regular giving	148,457	2,449	150,906	117,043	7,877	124,920
Donations, appeals and fundraising	4,673,890	863,468	5,537,358	4,259,076	733,754	4,992,830
Gift Aid	424,246	13,003	437,249	481,304	29,810	511,114
Legacies	1,072,065	-	1,072,065	311,971	-	311,971
	<u>6,318,658</u>	<u>878,920</u>	<u>7,197,578</u>	<u>5,169,394</u>	<u>771,441</u>	<u>5,940,835</u>

4. Income from charitable activities

Income from charitable activities includes a grant of £229,733 (2016: £197,633) from Children with Cancer UK to support our INSTINCT research programme at Newcastle University.

5. Exceptional income

During 2015/16 we received exceptional non-recurring donations totalling £2,889,949 in connection with the fundraising activities of one of our major donors. The donor remains an active supporter of The Charity but this level of financial support was not expected to recur this year. The income was restricted and will be used to fund research into paediatric low grade brain tumours.

6. Analysis of resources expended

	Direct Costs £	Grants £	Support Costs £	2017 Total £	2016 Total £
Raising funds	1,431,023	-	228,555	1,659,578	1,502,628
Charitable activities:					
Research	416,121	3,643,926	126,323	4,186,370	3,175,511
Patient Support	910,912	-	166,168	1,077,080	795,670
Campaigning and raising awareness	772,144	-	293,367	1,065,511	1,051,446
Total expenditure on charitable activities	<u>2,099,177</u>	<u>3,643,926</u>	<u>585,858</u>	<u>6,328,961</u>	<u>5,022,627</u>
Total expenditure	<u>3,530,200</u>	<u>3,643,926</u>	<u>814,413</u>	<u>7,988,539</u>	<u>6,525,255</u>

7. Research cost analysis

	2017 £	2016 £
Research programmes	2,028,551	1,644,786
Research projects	1,237,387	1,014,788
Clinical trials	219,609	42,553
Fellowships	146,361	75,595
Conferences	12,018	34,122
	<u>3,643,926</u>	<u>2,811,844</u>

A breakdown of research costs by individual award is provided in note 25.

8. Support costs by activity

	Finance and Human resources £	Central facilities £	Information technology £	Central management £	Governance £	Total £
Raising funds	79,760	66,949	62,376	5,115	14,355	228,555
Charitable activities:						
Research	31,876	26,756	24,929	2,044	40,718	126,323
Patient Support	58,472	49,080	45,728	3,750	9,138	166,168
Campaigning and raising awareness	106,356	89,272	83,176	6,821	7,742	293,367
2017 Total	<u>276,464</u>	<u>232,057</u>	<u>216,209</u>	<u>17,730</u>	<u>71,953</u>	<u>814,413</u>
2016 Total	<u>190,774</u>	<u>144,658</u>	<u>125,740</u>	<u>9,367</u>	<u>58,686</u>	<u>529,225</u>

9. Governance costs

	2017 £	2016 £
Auditor's remuneration	13,390	11,200
Premises costs and insurances	5,587	3,765
Trustee meeting	4,176	2,505
Legal and professional fees	1,263	1,861
Staff	47,537	39,355
	<u>71,953</u>	<u>58,686</u>

Trustees received no remuneration (2016: £nil). Five trustees were reimbursed for expenses in the year totalling £2,081 (2016: £2,111). The premium in respect of professional liability insurance covering trustee indemnity was £nil (2016: £nil).

10. Net incoming/(outgoing) resources for the year

	2017 £	2016 £
This is stated after charging:		
Auditor's remuneration	13,390	11,200
Depreciation	45,157	24,550
Pension costs	97,412	97,260
Lease payments	102,000	80,700

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £1,840,319 (2016: £3,432,161).

11. Staff costs

	2017 £	2016 £
Wages and salaries	2,295,342	1,867,075
Social security costs	220,086	181,174
Pension	97,412	97,260
	<u>2,612,840</u>	<u>2,145,509</u>

The average number of full time equivalent employees during the year was 80 (2016: 67).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2017	2016
£60,001 - £70,000	4	2
£70,001 - £80,000	2	-
£80,001 - £90,000	1	1

12. Taxation

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

13. Intangible fixed assets

Group and Company

	Computer Software £
Cost	
At 1 April 2016	66,023
Additions	54,689
At 31 March 2017	120,712
Depreciation	
At 1 April 2016	17,312
Charge for period	14,767
At 31 March 2017	32,079
Net Book Value	
At 31 March 2017	88,633
At 31 March 2016	48,711

14. Tangible fixed assets

Group and Company

	Leasehold Improvements £	Computers and Office Equipment £	Total £
Cost			
At 1 April 2016	59,569	107,214	166,783
Additions	-	17,477	17,477
At 31 March 2017	59,569	124,691	184,260
Depreciation			
At 1 April 2016	18,351	67,326	85,677
Charge for period	11,543	18,847	30,390
At 31 March 2017	29,894	86,173	116,067
Net Book Value			
At 31 March 2017	29,675	38,518	68,193
At 31 March 2016	41,218	39,888	81,106

15. Investment in subsidiary undertaking

Cost

	£
At 1 April 2016 and 31 March 2017	100

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing. At 31 March 2017 the aggregate of the share capital and reserves of TBTC Trading Ltd was £100 (2016: £100).

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, is donated to The Brain Tumour Charity.

	2017 £	2016 £
Turnover	70,737	79,615
Cost of sales	(21,077)	(32,368)
Gross profit	49,660	47,247
Other operating expenses	(34,306)	(23,634)
Profit before donation	15,354	23,613
Donation	(15,354)	(23,613)
Retained (loss)/profit	-	-

Cost of sales represent cost of stock sold in the year.

At the year end the aggregate assets of TBTC Trading Ltd were £16,826 (2016 £18,052), aggregate liabilities £16,726 (2016 £17,952) and shareholder's funds £100 (2016 £100).

16. Investments

Group and Company

	£
At 1 April 2016	8,959,443
Additions at cost	1,418,139
Disposals	(1,350,953)
Net unrealised gain/(loss) on revaluation	1,186,512
At 31 March 2017	10,213,141
Historical cost	9,275,358

	2017 £	2016 £
Investments at market value comprised:		
UK Equities	5,947,631	4,836,612
Absolute return funds	1,394,930	1,374,912
Fixed interest securities	2,870,580	2,723,221
Cash held within the investment portfolios	-	24,698
At 31 March 2017	10,213,141	8,959,443

During the year income from UK equity investments was £169,378 (2016: £148,913), income from fixed interest securities was £60,738 (2016: £55,670) and interest on deposits £22,654 (2016: £12,729).

17. Debtors

	Consolidated		Company	
	2017	2016	2017	2016
	£	£	£	£
Trade debtors	170,956	115,947	170,956	115,908
Accrued income and prepayments	230,006	319,413	222,506	311,913
Other debtors	643,086	3,506	643,086	3,506
	<u>1,044,048</u>	<u>438,866</u>	<u>1,036,548</u>	<u>431,327</u>

18. Creditors

	Consolidated		Company	
	2017	2016	2017	2016
	£	£	£	£
Grants payable	6,252,583	3,782,267	6,252,583	3,782,267
Accruals and deferred income	402,074	515,185	400,074	515,185
Creditors	105,106	305,368	105,106	303,371
Amounts owed to TBTC Trading Ltd		-	2,158	17,399
Other creditors	51,400	41,936	51,400	41,936
Social Security and other taxes	65,896	51,448	64,366	49,182
	<u>6,877,059</u>	<u>4,696,204</u>	<u>6,875,687</u>	<u>4,709,340</u>

19. Research commitments

At 31 March 2017 The Charity had authorised commitments that were subject to outstanding conditions amounting to £8,694,640 (2016: £6,691,364), these are expected to fall due as follows:

	2017	2016
	£	£
Within one year	3,007,642	2,367,786
Between one and two years	2,572,036	1,812,101
Between two and three years	1,576,004	1,656,401
Between three and four years	1,538,958	855,076
	<u>8,694,640</u>	<u>6,691,364</u>

During the first quarter of 2017/18 the Charity made six additional multi-year research awards, representing a total additional commitment of £4.1m.

20. Operating lease commitments

The total of future minimum property lease payments on operating leases expiring:

	Consolidated		Company	
	2017	2016	2017	2016
	£	£	£	£
Expiry date				
Between two and five years	110,500	216,750	78,000	153,000
	<u>110,500</u>	<u>216,750</u>	<u>78,000</u>	<u>153,000</u>

Operating lease charges during 2017 were £102,000 for property (2016: £80,700).

21. Analysis of net assets between funds

	Unrestricted Funds £	Restricted Funds £	Total 2017 £	Total 2016 £
Intangible fixed assets	88,633	-	88,633	48,711
Tangible fixed assets	68,193	-	68,193	81,106
Investments	10,213,141	-	10,213,141	8,959,443
Other current assets	4,301,681	4,197,572	8,499,253	5,767,045
Current liabilities	(5,423,100)	(1,453,959)	(6,877,059)	(4,696,204)
	<u>9,248,548</u>	<u>2,743,613</u>	<u>11,992,161</u>	<u>10,160,101</u>

22. Funds

Consolidated	At 1 April 2016	Incoming Resources	Resources Expended	Investment Gains	At 31 March 2017
Restricted funds:					
Research funds	425,923	681,830	(773,132)	-	334,621
Everest Fund	3,049,544	113,449	(1,155,746)	-	2,007,247
Awareness and knowledge funds	310,542	51,440	(242,592)	-	119,390
Support funds	30,382	512,725	(260,752)	-	282,355
	<u>3,816,391</u>	<u>1,359,444</u>	<u>(2,432,222)</u>	<u>-</u>	<u>2,743,613</u>
Unrestricted funds:					
General reserve	3,135,958	6,564,388	(5,153,939)	1,219,913	5,766,320
Designated funds	3,207,752	676,854	(402,378)	-	3,482,228
	<u>6,343,710</u>	<u>7,241,242</u>	<u>(5,556,317)</u>	<u>1,219,913</u>	<u>9,248,548</u>
	<u>10,160,101</u>	<u>8,600,686</u>	<u>(7,988,539)</u>	<u>1,219,913</u>	<u>11,992,161</u>
Company	At 1 April 2016	Incoming Resources	Resources Expended	Investment Gains	At 31 March 2017
Restricted funds:					
Research funds	425,923	681,830	(773,132)	-	334,621
Everest Fund	3,049,544	113,449	(1,155,746)	-	2,007,247
Awareness and knowledge funds	310,542	51,440	(242,592)	-	119,390
Support funds	30,382	512,725	(260,752)	-	282,355
	<u>3,816,391</u>	<u>1,359,444</u>	<u>(2,432,222)</u>	<u>-</u>	<u>2,743,613</u>
Unrestricted funds:					
General reserve	3,112,345	6,517,265	(5,098,557)	1,219,913	5,750,966
Designated funds	3,207,752	676,854	(402,378)	-	3,482,228
	<u>6,320,097</u>	<u>7,194,119</u>	<u>(5,500,935)</u>	<u>1,219,913</u>	<u>9,233,194</u>
	<u>10,136,488</u>	<u>8,553,563</u>	<u>(7,933,157)</u>	<u>1,219,913</u>	<u>11,976,807</u>

22 Funds continued

Purpose of restricted funds

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 25.
Everest fund	During 2015/16 we received exceptional income of £2,889,949 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours.
Awareness and knowledge funds	Awareness and knowledge funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is HeadSmart: be brain tumour aware.
Support funds	Funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated Funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition approved funding of a Chair position at a UK university has also been classed as designated funds.

23. **Related parties**

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd. TBTC Trading Ltd acts as a sales agent on behalf The Charity. At 31 March 2017 The Charity owed TBTC Trading Ltd £2,158 (2016: £17,399).

The registered office of TBTC Trading Ltd is:
Hartshead House
61-65 Victoria Road
Farnborough
Hampshire
GU14 7PA

Trustees made donations to The Charity totalling £3,360 during the year and paid contributions totalling £7,730 during a number of our fundraising events.

24. Grants receivable

During the year The Charity received support from the following trusts and foundations, where donations were restricted or designated the area of our activity is identified:

	£	Charitable activity:
BBC Children In Need	21,436	Sam's project
Children with Cancer UK	229,734	Newcastle - programme grant
Colin Oliphant Charitable Trust	30,000	Adult Early Diagnosis Campaign
DWF Foundation	3,000	Adult Early Diagnosis Research
Elizabeth & Prince Zaiger Charitable Trust	3,000	Paediatric research
Halifax Foundation for Northern Ireland	4,500	Support Services - Northern Ireland
Hugh Fraser Foundation	5,000	Local Support Services - Scotland
James Weir Foundation	3,000	Local Support Services - Scotland
Katy Holmes Trust	120,000	Newcastle - programme grant
Nationwide (Administration Centre)	2,000	Sam's project
Netherdale Trust	2,700	Local Support Services - Scotland
Ormsby Charitable Trust	1,500	Paediatric research
OSCAR's Paediatric Brain Tumour Charity	25,000	Quest for Cures Grant (Chesler)
Souter Charitable Trust	5,000	Local Support Services - Scotland
St James's Place Foundation	30,475	Sam's project
Tay Charitable Trust	1,000	Local Support Services - Scotland
The Ed Evans Foundation	10,000	Local Support Services - Wales
The Ellis Campbell Foundation	2,000	Headsmart Campaign
The Mugdock Children's Trust	1,000	Local Support Services - Scotland
The Sir James Reckitt Charity	8,000	Leeds - programme grant
The Sir James Reckitt Charity	12,000	Local Support Services - North
Bayfield Charitable Trust	1,000	
F J Wallis Charitable Settlement	5,000	
G M Morrison Charitable Trust	1,400	
Glossop Family Trust	200	
Hargrave Foundation for a Brighter Future	250	
Inchcape Foundation	500	
Individual	20	
Joseph Strong Frazer Trust	1,000	
Kevin and Deborah Gundle Philanthropic Trust	100	
Lilley Benevolent Trust	1,000	
Lloyds Bank Foundation	100	
Margot Lamond Charitable Trust	324	
Mazars Charitable Trust	80	
Peter Storrs Trust	2,000	
PwC	266	
Savannah Trust	98	
Sheila Whitley Trust	450	
South Square Trust	500	
Stay Strong Stu	65,000	
Stella Symons Charitable Trust	250	
The Bowler Family Charitable Trust	200	
The Dove Trust	173	
The Gentlemen's Night Out	25,000	
The Lillie C Johnson Charitable Trust	1,000	
The Madeline Mabey Trust	500	
The Vodafone Foundation	350	
The Yvette & Hermione Jacobson Charitable Trust	100	
Thomas C Maconochie Trust	200	
William Brake Charitable Trust	5,000	
Zurich Community Trust (UK) Limited	300	

Trusts and foundations also made £10,000 of anonymous donations.

25. Research awards

	2017	2016
	£	£
SGC Open Source	-	200,000
Edinburgh - Project - Dr Brennan	124,808	141,862
Heriot Watt - Project - Dr Leslie	-	66,923
Edinburgh - Project - Dr Brennan	-	87,710
Queens - Project - Mr Smith	-	95,485
Newcastle - Project - Prof Clifford - 16/49	-	13,655
Newcastle - Project - Prof Clifford - 16/164	-	59,514
Newcastle - Project - Prof Clifford - 16/92	-	(28)
Nottingham - Project - Prof Grundy - 17/86	-	(27,988)
Nottingham - Project - Prof Grundy - 17/199	-	(16,937)
Wolverhampton - Project	-	(38,260)
Cambridge - Project - Turner - 10/140	4,534	-
UCL - Project - Prof Brandner - 8/128	-	71,828
NCRI - Clinical Trials Project Officer - 8/196	-	(3,379)
UCL - Project - Dr Michod - 8/161	43,131	-
Glasgow - Project - Prof Chalmers - 26/160	62,348	-
Birmingham - Project - Dr. Tennant - 9/150	-	28,727
Cambridge - Project - Dr Watts - 10/136	-	58,316
Cambridge - Project - Mr Hart	-	50,000
Cambridge - Project - Prof Collins	(9,559)	31,992
Cambridge - Project - Dr Walter	28,546	65,277
UCL - Project - Dr Jacques - 8/152	-	23,821
QMUL - Project - Prof Sheer - 4/167	-	65,317
Birmingham - Project - Dr Peer - 9/204	-	66,066
UCL - Project - Dr. Clark	114,384	-
Southampton - Project - Prof Kennedy	107,361	-
Alder Hey - Project - Dr. Mallucci	34,307	-
Nottingham - Project - Dr. Dixon	98,549	-
Queensland - Project - Dr. Mazzieri	99,925	-
Cambridge - Project - Dr. Watts	100,000	-
Nottingham - Project - Dr. Rahman	81,359	-
Montreal - Project - Dr. Jahani-Asi	99,722	-
Kings - Project - Dr. Al-Jamal	98,462	-
Durham - Project - Dr. Gill	75,022	-
QMUL - Project - Dr. Ribeiro	74,488	-
 Bristol - Fellowship - Mr Singleton	 37,734	 37,431
Newcastle - Fellowship - Prof Clifford - 16/97	-	(267)
Nottingham - Fellowship - Adhikaree	38,472	38,164
QMUL - Fellowship - Dr. Millner	70,155	-
 Research awards sub-total carried forward	 1,383,748	 1,115,229

25. Research awards (continued)

	2017 £	2016 £
Research awards sub-total brought forward	1,383,748	1,115,229
UCL - Programme - Prof Salomoni - 8/197	7,603	321,171
UCL - Programme - Dr Pollard - 8/105	(13,857)	-
Newcastle - Programme - Prof Clifford - 16/193	466,484	402,460
Leeds - Programme - Prof Short 13/192	236,000	218,000
Edinburgh - Programme - Dr Pollard	-	277,761
ICR - Programme - Prof Chesler	-	237,307
Nottingham - Programme - Prof Grundy - 17/188	-	188,086
Blizzard - Programme - Prof Sheer	200,000	-
German CRC - Programme - Dr. Jones	1,132,321	-
Cambridge - Clinical Trial - Dr Baird - 10/172	10,805	-
Plymouth - Clinical Trial - Prof Hanemann - 30/117	-	(24,846)
UCL - Clinical Trial Support - Dr Smith - 8/56	-	-
Birmingham - Clinical Trials Nurse - 3/173	-	712
Birmingham - Clinical Trial - Dr Picton - 9/201	13,259	12,935
Manchester - Clinical Trial - Dr Whitfield - 28/203	-	8,307
Birmingham - Clinical Trial - Dr Hargrave	23,220	20,599
Leeds - Clinical Trial - Dr. Samson	19,541	-
Birmingham - Clinical Trial Support - Dr. Kearns	88,507	-
Glasgow - Clinical Trial - Prof Chalmers	31,104	-
Leeds - Clinical Trial - Prof Short	25,009	-
Paradigm Sample Collection - Clinical Trial	8,164	10,123
Symposium - PIGS2 Paediatric Infiltrating Glioma	-	10,000
Cambridge - Nurse conference - Ms Oberg	-	5,000
Research Conferences	-	4,200
Neuro-oncology Boot Camp	-	4,800
Glasgow - Conferences - Prof Chalmers	2,658	-
NCRI - Meetings - Dr. Watts	4,160	-
NHS Lothian - Meetings - Dr. Grant	2,000	-
Glasgow - Meetings - Prof Chalmers	2,850	-
Other conferences	350	-
	<u>3,643,926</u>	<u>2,811,844</u>